Disclosed are pyridopyrazine compounds of formula (I) where the substituents are as defined herein, for example 3-(7-(4-(dimethylamino)phenyl)pyrido[4,3-b]pyrazin-5-ylamino)propanamide and N-((1-methyl piperidin-3-yl)methyl)-7-(4-morpholinophenyl)pyrido[4,3-b]pyrazin-5-amine and pharmaceutical compositions thereof. Also disclosed are methods of use of the compounds for example in the treatment of Syk kinase mediated diseases such as allergic asthma, allergic rhinitis, rheumatoid arthritis, multiple sclerosis, lupus, systemic lupus, erythematosus, lymphoma, B cell lymphoma, T cell lymphoma, leukemia, myelodysplasic syndrome, anemia, leucopenia, neutropenia, thrombocytopenia, granuloctopenia, pancytoia or idiopathic thrombocytopenic purpura.
